ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Cardiovascular Outcomes of Kidney Transplant Recipients Receiving Belatacept Compared to a Matched Tacrolimus

Y. Kim1, J. Marvin1, K. Belfield1, G. Girone1, R. Formica2, E. Cohen1

1Pharmacy, Yale New Haven Hospital, New Haven, CT, 2Section of Nephrology, Yale School of Medicine, New Haven, CT

Meeting: 2022 American Transplant Congress

Abstract number: 787

Keywords: Hyperglycemia

Topic: Clinical Science » Kidney » 35 - Kidney: Cardiovascular and Metabolic Complications

Session Information

Session Name: Kidney: Cardiovascular and Metabolic Complications

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: Tacrolimus (TAC), a calcineurin inhibitor (CNI), is the backbone of maintenance immunosuppression in kidney transplant recipients (KTR) but has been associated with cardiovascular (CV) events. As CV disease is the leading cause of death in KTR, various CNI-free regimens have been explored. Belatacept (BELA), a co-stimulatory inhibitor, is an alternative with a favorable adverse event profile; however, there is limited data comparing its CV effects with TAC. This study was designed to investigate CV effects of BELA compared to TAC in KTR.

*Methods: In this retrospective cohort study, KTR who received BELA either de novo or conversion from 1/2013-10/2020 were matched 1:1 to TAC based on transplant date, age, duration of dialysis, body mass index (BMI), pre-transplant diabetes and any history of cardiovascular accident (CVA), myocardial infarction (MI), coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI) or peripheral artery disease revascularization. Patients with less than 3 months of follow-up or 1 follow-up annually were excluded. The primary outcome was the composite of hospitalization for heart failure, CVA, MI, CABG, PCI and CV death. Secondary outcomes included graft failure, acute rejection, death, post-transplant diabetes (PTDM) and change in BMI and hemoglobin A1c (HbA1c). Outcomes were assessed starting from the date of initial BELA dose or equivalent time post-transplant for the TAC cohort and were analyzed using Fisher’s exact test, chi-square test, Wilcoxon test, Student’s t-test, two-way ANOVA and repeated-measures mixed-effects models where appropriate.

*Results: A total of 114 KTR were included in the analysis. Mean duration of follow-up (±SD) was 1267 ± 639 days on BELA and 1210 ± 625 days on TAC. There was no significant difference in baseline characteristics or the primary outcome (P=0.77) (Table 1). PTDM was observed less frequently with BELA compared to TAC (P=0.03). HbA1c decreased significantly with BELA compared to TAC in KTR without preexisting diabetes (Mean Difference, -0.69; 95% CI, -1.30 to -0.08).

*Conclusions: BELA did not reduce major CV events compared to TAC. BELA was associated with decreased incidence of PTDM overall and a reduction in HbA1c in patients without pre-transplant diabetes. Further studies are needed to assess long term CV outcomes.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Kim Y, Marvin J, Belfield K, Girone G, Formica R, Cohen E. Cardiovascular Outcomes of Kidney Transplant Recipients Receiving Belatacept Compared to a Matched Tacrolimus [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/cardiovascular-outcomes-of-kidney-transplant-recipients-receiving-belatacept-compared-to-a-matched-tacrolimus/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences